Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 5/20 | 0.50 |
| ▸ | CDK2 | P24941 | 5/20 | 0.50 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.42 |
| ▸ | PDE8A | O60658 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005006 | 0.85 | CDK1 (0.46) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL3856920 | 0.78 | CCNE1 (0.48) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL3856913 | 0.77 | FGFR1 (0.48) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL1672138 | 0.72 | CDK1 (0.62) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL30052313 | 0.72 | CDK1 (0.62) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL431825 | 0.71 | CDK1 (0.61) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL13715017 | 0.71 | CCNE1 (0.54) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL3850990 | 0.70 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3859183 | 0.70 | CDK1 (0.49) | CCNE1CDK2CDK1CCNB1HSP90AB1 | |
| SCHEMBL3859201 | 0.70 | CDK1 (0.49) | CCNE1CDK2CDK1CCNB1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | CCNE1 522/4885CDK2 323/4885CDK1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.